The AHEAD study is a Phase III, double-blinded, placebo-controlled study with a parallel treatment arm sponsored by Eisai and the Alzheimer's Clinical Trials Consortium (ACTC). AHEAD is a combination of two trials – the A45 trial and A3 trial. This is a 6 to 7 year study that seeks to enroll a total of 1,400 participants across 100 global study sites during a 2-3 year period. Eligible participants will be randomly assigned into one of two groups and will receive either the investigational medication, BAN2401, or placebo for 4 years.
What is the purpose of the AHEAD Study?
The purpose of the AHEAD study is to determine if the investigational medication, BAN2401, is superior to a placebo in terms of maintaining normal cognitive abilities and how effective it is in reducing levels of amyloid and tau plaques in the brain using amyloid PET and tau PET scans. The safety and tolerability of BAN2401 as compared to placebo is also being studied. A placebo is an inactive substance that is designed to look like a medication.
This study is for men and women aged 55-80 who are cognitively normal and have a study partner. Interested participants can contact the Memory and Aging Program Outreach Team at 401-455-6402 or by sending an email email@example.com discuss additional eligibility criteria.